Broadcast Date: 
  • Time: 

Epigenetics is among the most rapidly burgeoning fields within fundamental and applied  R&D—presenting significant opportunities for the drug discovery process. Over the past several years, advances have led to a greater understanding of basic epigenetic mechanisms mediated by histone and DNA  modifications. Consequently, the recognition of the critical role that  epigenetic modifications play in the incidence and progression of human disease has progressed significantly.

Unsurprisingly, efforts to identify clinically therapeutic interventions for anomalous epigenetic states associated with disease have increased dramatically. However, with the promise of potential therapeutics also comes the demand for effective tools to investigate and measure these molecular events. Researchers are searching for platform technologies that offer high biological relevance with sensitivity, robustness, and throughput inherent to the analytical methods they have come to rely on.

In this GEN webinar our panelists will present their methods for measuring epigenetic changes in model systems and how research tools from PerkinElmer have assisted their drug discovery research.

Our first presenter, Michael-Christopher Keogh, Ph.D., Director of Markets and Application Development at EpiCypher, will discuss his use of full-length histones and nucleosomes as more biologically relevant  substrates for epigenetic enzymes.

The second presentation will be given by Roya Pedram Fatemi, Ph.D. candidate in the Molecular and Cellular Pharmacology program at the  University of Miami Miller School of Medicine. Ms. Fatemi will describe her recent work on long noncoding RNA-epigenetic enzyme interactions as a novel class of drug targets for the upregulation of therapeutic genes.

Who Should Attend

  • Epigeneticists
  • Drug development scientists
  • Molecular biologists
  • Principal investigators
  • Cell biologists

You Will Learn

  • How epigenetic reader, writer, and eraser enzymes coordinate the molecular machinery of the cell and can be engineered to enhance rational drug design methods.
  • The importance of lncRNAs as regulators of cell functions through interactions with epigenetic enzymes.
  • How Perkin Elmer epigenetic instrumentation can help streamline your drug discovery workflow.

Produced with support from:

Sponsor Logo


Michael-Christopher Keogh, Ph.D.
Director, Markets and Application Development,

Roya Pedram Fatemi,
University of Miami Miller School of Medicine